XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.
P
P

Pfizer


뉴스

UK regulator authorises updated Pfizer-BioNTech COVID shot targeting JN.1 strain

UPDATE 1-UK regulator authorises updated Pfizer-BioNTech COVID shot targeting JN.1 strain Adds details in paragraphs 2 & 3 July 24 (Reuters) - Britain's health regulator said on Wednesday it has authorised Pfizer PFE.N and BioNTech's 22UAy.DE updated COVID-19 vaccine that targets the JN.1 subvariant for use in infants, children and adults. The Medicines and Healthcare products Regulatory Agency (MHRA) said it has approved four forms of the adapted Comirnaty JN.1 vaccine after reviewing its safet
P

UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant

UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant July 24 (Reuters) - Britain's health regulator said on Wednesday it has authorised Pfizer PFE.N and BioNTech's 22UAy.DE updated COVID-19 vaccine that targets the JN.1 subvariant of the coronavirus for use in infants, children and adults. Reporting by Unnamalai L in Bengaluru; Editi
P

UK's MHRA Approved An Adapted Pfizer/Biontech Covid-19 Vaccine (Comirnaty) That Targets The Jn.1 Covid-19 Subvariant

BRIEF-UK's MHRA Approved An Adapted Pfizer/Biontech Covid-19 Vaccine (Comirnaty) That Targets The Jn.1 Covid-19 Subvariant July 24 (Reuters) - UK's MHRA: UK'S MHRA: APPROVED AN ADAPTED PFIZER/BIONTECH COVID-19 VACCINE (COMIRNATY) THAT TARGETS THE JN.1 COVID-19 SUBVARIANT UK'S MHRA: FOUR FORMS OF THIS ADAPTED COMIRNATY JN.1 VACCINE HAVE BEEN APPROVE
P

Sangamo rises on bleeding disorder gene therapy trial data

BUZZ-Sangamo rises on bleeding disorder gene therapy trial data ** Shares of gene therapy developer Sangamo Therapeutics SGMO.O rise ~73.6% to 67 cents premarket ** SGMO says co and partner Pfizer's PFE.N gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study *
P

Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial

UPDATE 1-Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial Adds background on data and disorder throughout July 24 (Reuters) - Pfizer's PFE.N gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment, the company said on Wednesday.
B
P

Pfizer Announces Positive Topline Results From Phase 3 Study Of Hemophilia A Gene Therapy Candidate

BRIEF-Pfizer Announces Positive Topline Results From Phase 3 Study Of Hemophilia A Gene Therapy Candidate July 24 (Reuters) - Pfizer Inc PFE.N : PFIZER ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY OF HEMOPHILIA A GENE THERAPY CANDIDATE PFIZER: ANALYSES OF FULL PHASE 3 DATASET FROM AFFINE STUDY ONGOING PFIZER: IN AFFINE STUDY, GIROCTOCOGENE
P

Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial

Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial July 24 (Reuters) - Pfizer PFE.N said on Wednesday that its gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment.
P

Merck's RSV shot helps protect infants in mid-to-late stage study

UPDATE 3-Merck's RSV shot helps protect infants in mid-to-late stage study Adds analyst comment in paragraph 3 By Vaibhav Sadhamta July 23 (Reuters) - Merck's MRK.N antibody-based shot met the main goal of a mid-to-late stage trial, when tested to protect infants against a disease caused by the respiratory syncytial virus (RSV), the company said on Tuesday.
A
P
S

GSK's Viiv Healthcare Announces Positive New Data For Apretude Use During Pregnancy

BRIEF-GSK's Viiv Healthcare Announces Positive New Data For Apretude Use During Pregnancy July 23 (Reuters) - GSK plc GSK.L : GSK: VIIV HEALTHCARE ANNOUNCES POSITIVE NEW DATA FOR APRETUDE USE DURING PREGNANCY GSK: VIV'S FINDINGS SHOW MATERNAL AND PREGNANCY OUTCOMES WITH APRETUDE EXPOSURE WERE COMPARABLE TO THOSE WITH NO CABOTEGRAVIR EXPOSURE Source
G
P

Collaboration software maker Smartsheet fields buyout interest, sources say

EXCLUSIVE-Collaboration software maker Smartsheet fields buyout interest, sources say Adds share reaction in paragraph 4 By Milana Vinn and Anirban Sen July 18 (Reuters) - Smartsheet SMAR.N , a U.S. maker of workplace collaboration software with a market value of $6.6 billion, has tapped investment bankers after attracting acquisition interest from buyout firms, according to people familiar with the matter.
C
P

Collaboration software maker Smartsheet fields buyout interest, sources say

EXCLUSIVE-Collaboration software maker Smartsheet fields buyout interest, sources say By Milana Vinn and Anirban Sen July 18 (Reuters) - Smartsheet SMAR.N , a U.S. maker of workplace collaboration software with a market value of $6.3 billion, has tapped investment bankers after attracting acquisition interest from buyout firms, according to people familiar with the matter.
C
P

Novo Nordisk obesity feast no longer a free lunch

BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, July 18 (Reuters Breakingviews) - Novo Nordisk NOVOb.CO is going to have to work hard to justify its bulging valuation. The $603 billion obesity drug maker’s shares have more than trebled since 2021 thanks to insatiable appetite for its weight-loss drug.
A
P
R
I

Valneva Says Co And Pfizer Announce Primary Vaccination Series Completion

BRIEF-Valneva Says Co And Pfizer Announce Primary Vaccination Series Completion July 17 (Reuters) - Valneva SE VLS.PA : PHASE 3 VALOR LYME DISEASE TRIAL: VALNEVA AND PFIZER ANNOUNCE PRIMARY VACCINATION SERIES COMPLETION VALNEVA - PRIMARY VACCINATION SERIES TO BE FOLLOWED BY A BOOSTER APPROXIMATELY ONE YEAR AFTER COMPLETION VALNEVA SE: PFIZER PLANS TO SUBMIT A BIOLOGICS LICENSE APPLICATION (BLA) TO U.S.
P

Mark Cuban's Cost Plus to import penicillin to address US shortage (July 17)

CORRECTED-Mark Cuban's Cost Plus to import penicillin to address US shortage (July 17) Removes reference in July 17 story to Pfizer's pediatric version of Bicillin-L-A in paragraph 3 July 17 (Reuters) - Mark Cuban's Cost Plus Drug Company said on Wednesday that it is working with the U.S. Food and Drug Administration to import and distribute penicillin in the country temporarily.
P

Weight-loss drug developers line up to tap market worth $150 billion

FACTBOX-Weight-loss drug developers line up to tap market worth $150 billion Updates with latest details on Pfizer, Roche and Carmot Therapeutics July 17 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the early 2030s.
A
O
P
R

Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason

Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason JERUSALEM, July 17 (Reuters) - Israel's CytoReason, which uses AI to develop disease models, said on Wednesday it had raised $80 million in a private funding round. Nvidia NVDA.O , Pfizer PFE.N , Thermo Fisher TMO.N and venture capital investor OurCrowd participated in the round, CytoReason said.
N
P
T

EU court criticises Commission over handling of COVID vaccine contracts

UPDATE 3-EU court criticises Commission over handling of COVID vaccine contracts Adds more reaction from Commission in paragraphs 8-10 By Foo Yun Chee and Bart H. Meijer BRUSSELS, July 17 (Reuters) - Europe's second-highest court on Wednesday criticised the European Commission for a lack of transparency over COVID-19 vaccine contracts four years ago, a day before a key vote on Commission head Ursula von der Leyen's bid for a second term.
A
P
S

Roche touts early trial success of second obesity drug candidate

UPDATE 4-Roche touts early trial success of second obesity drug candidate Adds executive comment from paragraph 11 By Ludwig Burger and Paolo Laudani July 17 (Reuters) - Roche ROG.S said on Wednesday a second drug candidate from its purchase of Carmot Therapeutics yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs.
P
R

U.S. STOCKS Pure Cycle, Tesla, Five9

BUZZ-U.S. STOCKS ON THE MOVE-Pure Cycle, Tesla, Five9 Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 fell from record highs on Thursday, weighed by megacap stocks, as investors favored small-caps after a softer-than-expected inflation reading bolstered hopes that the U.S.
A
A
B
C
C
C
F
I
P
P
P
T
V
D
W
U
U
E

U.S. STOCKS Delta Air Lines, Crypto stocks, Solar stocks

BUZZ-U.S. STOCKS ON THE MOVE-Delta Air Lines, Crypto stocks, Solar stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes struggled for direction on Thursday as investors favored rate-sensitive small-cap stocks over expensive megacaps after a softer-than-expected inflation reading bolstered hopes for monetary policy easing in September.
A
B
C
C
F
N
P
P
P
V
L
A
W
U
U
I
M
R



조건

인기 자산

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.